Douglas Miehm
Stock Analyst at RBC Capital
(3.50)
# 884
Out of 5,072 analysts
51
Total ratings
48.89%
Success rate
6.68%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $16.20 | +17.28% | 14 | Nov 14, 2025 | |
| MNKD MannKind | Maintains: Outperform | $8 → $7.5 | $5.38 | +39.41% | 4 | Nov 11, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $16.37 | -8.37% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.25 | +60.00% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.04 | +380.77% | 1 | Mar 10, 2025 |
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $16.20
Upside: +17.28%
MannKind
Nov 11, 2025
Maintains: Outperform
Price Target: $8 → $7.5
Current: $5.38
Upside: +39.41%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $16.37
Upside: -8.37%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.25
Upside: +60.00%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.04
Upside: +380.77%